Clinical and neuropathological diversity of tauopathy in MAPT duplication carriers

David Wallon1, Susana Boluda2,3, Anne Rovelet-Lecrux4

  • 1Normandie Univ, UNIROUEN, Inserm U1245, CHU Rouen, Department of Neurology and CNR-MAJ, F-76000, Rouen, France. david.wallon@chu-rouen.fr.

Insights

Microduplications in the MAPT gene region cause a primary tauopathy, presenting diverse neurological and cognitive symptoms. This condition involves abnormal Tau protein accumulation, mimicking Alzheimer's disease but lacking amyloid plaques.

Area of Science:

  • Neuroscience
  • Genetics
  • Neuropathology

Background:

  • Microduplications of the 17q21.31 chromosomal region, including the MAPT gene, are linked to progressive neurological disorders.
  • These disorders can mimic Alzheimer's disease with memory impairment and behavioral changes.
  • Pathological findings reveal a primary tauopathy with mixed 3R and 4R tau inclusions, distinct from typical Alzheimer's pathology.

Purpose of the Study:

  • To delineate the phenotypic spectrum of MAPT duplications.
  • To investigate the clinical, imaging, and neuropathological features of MAPT duplication carriers.
  • To understand the tau aggregation characteristics in MAPT duplication-associated tauopathy.

Main Methods:

  • Clinical assessment of ten MAPT duplication carriers from nine families.
  • Cerebrospinal fluid analysis, MRI, dopamine transporter scans, and PET imaging (amyloid and Tau tracers).
  • Neuropathological examination of brain tissue and in vitro tau seeding experiments.

Main Results:

  • Onset ranged from 37-57 years, with 8/10 patients experiencing memory impairment; two presented with extrapyramidal syndrome and gait issues.
  • Amyloid PET was negative; Tau PET showed mesiotemporal cortex deposits. Dopaminergic denervation was observed in all scanned patients.
  • Neuropathology confirmed tauopathy with varying 3R/4R tau aggregate ratios, correlating with clinical presentation (cortical for 3R, basal ganglia/midbrain for 4R).

Conclusions:

  • MAPT duplication leads to a primary tauopathy with a broad clinical and neuropathological range.
  • The tau aggregate composition (3R vs. 4R) influences the clinical phenotype, from cognitive/behavioral to extrapyramidal syndromes.
  • In vitro seeding assays reveal tau aggregate characteristics intermediate between Pick's disease and progressive supranuclear palsy.